Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.

Fiche publication

Date publication

décembre 2020

Journal

Neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal , Pr ENTZ-WERLE Natacha

Tous les auteurs :
Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33377141

Résumé

High-risk medulloblastoma are defined by the presence of metastatic disease and/or incomplete resection and/or unfavorable histopathology and/or tumors with MYC amplification. We aimed to assess the 3-year progression-free survival (PFS) and define the molecular characteristics associated with PFS in patients aged 5 to 19 years with newly diagnosed high-risk medulloblastoma treated according to the phase 2 trial PNET HR+5.